<DOC>
	<DOCNO>NCT02857920</DOCNO>
	<brief_summary>The aim study safety efficacy Bevacizumab plus natural killer ( NK ) immunotherapy many kind recurrent solid tumor .</brief_summary>
	<brief_title>Combination Bevacizumab NK Immunotherapy Recurrent Solid Tumors</brief_title>
	<detailed_description>By enrol patient recurrent solid tumor adapt enrolled criterion , study document first time safety short long term efficacy combine therapy use Bevacizumab NK cell . The safety evaluate statistic adverse reaction . The efficacy evaluate accord local relief degree , progress free survival ( PFS ) overall survival ( OS ) .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>All standard therapy fail accord NCCN guideline patient refuse standard therapy cancer recurrence Body tumor 16 , maximum tumor length &lt; 5 cm KPS ≥ 70 , lifespan &gt; 6 month Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L , neutrophil count ≥ 2×109/L , hemoglobin ≥ 80 g/L Patients cardiac pacemaker Patients brain metastasis Patients grade 3 hypertension diabetic complication , severe cardiac pulmonary dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vascular Endothelial Growth Factor ( VEGF ) antibody</keyword>
	<keyword>solid tumor</keyword>
	<keyword>NK Immunotherapy</keyword>
</DOC>